1 Cardiovascular risk calculator for diabetic patients 이해영서울대학병원순환기내과
2 Contents Need of risk engine for diabetic patients Three main approaches of global cardiovascular risk estimation in diabetes Validation of cardiovascular risk scores for diabetic patients Impact of cardiovascular risk assessment on clinical practice and outcomes Summary and conclusion
3 Diabetes mellitus as CVD equivalent Survival (%) Nondiabetic subjects without prior MI Diabetic subjects without prior MI Nondiabetic subjects with prior MI Diabetic subjects with prior MI Year Haffner et al. N Engl J Med. 1998;339:
4 High prevalence of CAD among diabetic patients % of patients Type 2 diabetes Non-diabetes /3 of diabetic patients die of cardiovascular disease, including CHD, stroke, and peripheral vascular disease >65 Ages Harris MI, National Diabetes Data group
5 JAMA, Nov
6 > 20% of high risk diabetic patients have significant degree of coronary artery stenosis Study population Men: 50 YO with 3 yrs of DM or 40 YO with 5 yrs of DM Women: 55 YO with 3 yrs of DM or 45 YO with 5 yrs of DM Use of antidiabetic medication for 1 year No Hx of ASCVD Highest degree of CCTA stenosis Normal: 31.3% Mild: 46.1% Moderate (50-69%, CAC score > 100): 11.9% Severe (>70%): 10.7%arial
7 No significant difference in primary endpoint (Death/MI/Unstable Angina) HR = 0.80 ( )
8 Diabetes mellitus position statement In asymptomatic patients, routine (& general) screening for coronary artery disease is not recommended, because it does not improve outcomes as long as CVD risk factors are treated May be due to wide application of risk factor management, the overall CV event rate becomes lower than previous era
9 Diabetes mellitus position statement In asymptomatic patients, routine (& general) screening for coronary artery disease is not recommended, because it does not improve outcomes as long as CVD risk factors are treated May be due to wide application of risk factor management, the overall CV event rate becomes lower than previous era
10 Overall CV risk in diabetic patients lower than 20%... Detection of Ischemia in Asymptomatic Diabetics [DIAD] pts with DM (mean age 61%, ½ ), ½ got myocardial perfusion imaging, f/u 5yrs No diff: MI/CAD death: 2.7% screened vs 3% not No others significantly diff either DYNAMIT pts with DM + > 2 CV risk factors Treadmill test 21.5 % prevalence of silent ischemia f/u 3.5yrs No diff: MI/CAD death: 2.6% screened vs 2.4% not No others significantly diff either.
11 Suggested flow chart for CV prevention stratified for high risk diabetic patients
12 Contents Need of risk engine for diabetic patients Three main approaches of global cardiovascular risk estimation in diabetes Validation of cardiovascular risk scores for diabetic patients Impact of cardiovascular risk assessment on clinical practice and outcomes Summary and conclusion
13 Overview of notion of global risk assessment Coefficient of each risk factor indicates their relative contribution to overall CVD risk. Risk models developed using logistic or survival regressions Validation based on Derivation sample (internal validation) Independent populations (external validation) Discrimination ability to correctly classify individuals who go on to develop a CV event and those who remain event free Characterized by AUC or the C-statistic C-statistic ranges from 0.5 (uninformative test) to 1.0 (perfect discrimination) In general, a C-statistic > 0.7 considered acceptable Calibration: concordance between predicted risk and observed risk assessed by comparing risk estimates from the model with actual event rates in the test population Recalibration of the risk model by adjusting the baseline risk estimates to fit the target population Reclassification: change in risk categories subsequent to adding a newly described risk factor or marker to an existing model
14 3 approaches of global CV risk estimation in diabetes CVD risk equivalent (20% risk) approach Unifying risk models regardless DM status Separate models for diabetic patients
15 CVD risk equivalent (20% risk) approach Classifying all individuals with diabetes as having a 10-year absolute CVD risk of at least 20%. CVD risk is not uniformly distributed among people with diabetes. Various studies suggests that multivariable risk prediction to be significantly better than classification of diabetes as a cardiovascular risk equivalent Using ATPIII models, 71.9% of the diabetic WHS participants had a predicted 10-year risk < 20%.
16 Unifying risk models regardless DM status Global CVD risk assessment for people with or without diabetes. The rationale is that there is not interaction between the diabetes status and other cardiovascular risk factors. everything else being equal a subject with diabetes will not always have a higher risk than non-diabetic subject with the same level of other risk factors (e.g., blood pressure) Framingham cardiovascular risk equations, Pooled cohort equations
17 Characteristics of cardiovascular risk scores
18 Separate models for diabetic patients Risk factors affect cardiovascular disease risk in different ways in people with and without diabetes. Assumed that duration of diagnosed diabetes will contribute more to risk estimates than age increment. Therefore to allow a more rational use of predictive information from age in people with diabetes, it has to be split into two components (i.e. age at diabetes diagnosis, known duration of diabetes). Classical CV risk factors including smoking, BP, lipid might affect CVD risk similarly in people with and without diabetes, with no evidence of interaction. Risk factors having diabetes-specific characteristics Prescriptions of cardiovascular risk reducing therapies Hemoglobin A1c (HbA1c) Urinary albumin excretion Marker of microvascular complications (especially retinopathy) Constructing different model for diabetic patients allows efficient use of predictive information captured by diabetes-specific factors UKPDS risk engines, etc
19 Schema for estimating the 4-year risk of CVD by the ADVANCE model equation
20 Cardiovascular risk models for T2DM Cardiovascular disease prediction models Action in Diabetes and Vascular disease: 5yr PreterAx and diamicron-mr Controlled Evaluation (ADVANCE) risk engine: 4yr Fremantle risk score: 5yr New Zealand Diabetes Cohort Study (DCS) risk score: 5yr Swedish National Diabetes Registry risk score: 5yr Cardiovascular Health Study (CHS) risk score:10yr Coronary heart disease prediction models DCS risk score: 5yr Diabetes Audit and Research in Tayside Scotland (DARTS) risk score: 5yr Hong Kong Diabetes Register risk score: 5yr Atherosclerosis Risk in Communities (ARIC) risk score: 10yr UKPDS risk engine: 5yr
21 Contents Need of risk engine for diabetic patients Three main approaches of global cardiovascular risk estimation in diabetes Validation of cardiovascular risk scores for diabetic patients Impact of cardiovascular risk assessment on clinical practice and outcomes Summary and conclusion
22 Framingham equation under-estimate CHD risk in diabetes up to 50% Predicted Observed UKPDS CHD event (%/yr) (Diabetes) WOSCOPS CHD event (%/yr) (Non-diabetes) (Yeo et al Diabet Med 2001; 18: ) Cardiff CHD event Male (Diabetes) (% / 4 yrs) Female Stevens et al Diabet Med 2005; 22: 228
23 Why under-estimation? Model based on largely non-dm population (Framingham calculator) Traditional risk factors do not account for excess CHD death in diabetes. Other important factors not included in risk calculation (ie small dense LDL, microalbuminuria, hypercoagulable state, impaired fibrinolysis, endothelial dysfunction, inflammatory states, insulin resistance etc)
24 UKPDS risk engine is not a better alternative Comparison between UKPDS risk engine and Framingham equation SH Song et al Diabetic Med 2004; 21: Mean CHD risk (over 10 yrs) in type 2 diabetes UKPDS risk engine better 15% threshold Framingham calculator better male female JBS UKPDS Conclusion: Overall, UKPDS risk engine estimated higher CHD risk score. At high risk (>30%), UKPDS risk engine consistently estimated higher risk score than Framingham equation. At lower risk levels (~15%) where clinical decision to start statin occurs (as per NICE), UKPDS risk engine and Framingham equation equivalent.
25 UKPDS risk engine overestimates CHD/CVD risk External validation using 1861 T2DM patients from EPIC-NL, EPIC-Potsdam cohort By UKPDS risk engine the mean predicted 8 year risk was 15.9% while the observed 8 year CHD risk was 4.9%, resulting in an overestimation of 224%. For 8 year CVD risk, the UKPDS risk engine overestimated the CVD risk by 112%, as the observed 8 year CVD risk was 7.5%. Discriminative ability is moderate (c-statistics ) and the calibration poor, with a severely overestimated CHD risk prediction.
26 UKPDS risk engine overestimates CHD/CVD risk Calibration plots for 5 year calculated risk for (a) CHD and (b) CVD. Values depict observed and predicted values with 95% CI. The dotted 45 line denotes ideal agreement between predicted and observed risk.
27 van der Leeuw J, et al. Heart 2015;101:
28 Moderate discrimination power Discrimination was moderate for all 10 prediction models, with c-statistics ranging from 0.54 (95% CI 0.46 to 0.63) to 0.76 (95% CI 0.67 to 0.84). Discrimination in external validation using EPIC-NL, EPIC- Potsdam and Secondary Manifestations of ARTerial disease (SMART).
29 Overestimation of risk Expected to observed ratio of the prediction models in EPIC-NL, EPIC-Potsdam and SMART
30 Overestimation mainly occurs in high-risk patients
31 Why overestimate? UKPDS risk engine was developed from a cohort that started including patients in Treatment of type 2 diabetes and prevention of CVD has improved since 1977 and the risk of developing CVD has declined with better treatment of type 2 diabetes As diabetes is now detected at an earlier stage, therapeutic intervention can be initiated earlier, reducing CVD risk even further. Modifiable risk factors have changed over time: smoking is less common and there are better treatments for hypertension and to lower HbA1c concentrations. The slight overestimation of risk in high risk is probably less relevant in clinical practice as these patients would meet the treatment threshold anyway, even if actual risk is somewhat lower.
32 Contents Need of risk engine for diabetic patients Three main approaches of global cardiovascular risk estimation in diabetes Validation of cardiovascular risk scores for diabetic patients Impact of cardiovascular risk assessment on clinical practice and outcomes Summary and conclusion
33 Impact studies of the CVD prediction models 3 studies used a randomised controlled trial design and examined the impact of the Framingham prediction model on treatment and prevention of CVD. Half of them allocated to an intervention group for which CV prediction model was noted on the patient s records, while in control group it was not. No difference observed in prescription of glucose control, blood pressure lowering and lipid-modifying treatments. However, restricting analysis to the high-risk group, patients in the intervention group were more likely to receive lipid-modifying or blood pressure-lowering prescriptions. Hall LE, et al. British Medical Journal. 2003;326:251-2
34 Individualized CAD screening in asymptomatic diabetic patients based on risk score model Classical risk factors + DM characteristic factors (duration of diabetes, ratio of total cholesterol to HDL, neuropathy) Medicine. 2015;94:e508
35 Incorporation of CVD prediction models in clinical guidelines IDF21 and NICE guidelines: UKPDS risk engine Canadian Diabetes Association: UKPDS risk engine, PROCAM, Strong Heart prediction model EASD: Framingham, DECODE Australian National Vascular Disease Prevention Alliance: Framingham prediction model, UKPDS risk engine JBS developed risk charts based on the Framingham prediction model
36 Summary and conclusion Current diabetes guidelines do not recommend routine screening for coronary artery disease in asymptomatic patients. But it is suggested that those at highest risk (10- yr risk 20%) for cardiac events may benefit from cardiovascular screening. The risk calculation can assist clinicians to identify T2DM patients with low or high risk of CVD. There is tendency of overestimation in high risk patients, however it is less relevant in clinical practice as these patients would meet the treatment threshold anyway, even if actual risk is somewhat lower. To enhance prediction of CVD and CHD in patients with T2DM, there is a need to update or construct a new and improved diabetes-specific model with better performance and better external validity.
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL SCHOOL DOCTORATE THESIS - Summary CHRONIC COMPLICATIONS IN PATIENTS WITH TYPE 1 DIABETES MELLITUS - Epidemiological study - PhD Manager: Professor PhD.
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
Prevention of Cardiovascular Disease in Children with Diabetes Stephen R. Daniels, MD, PhD Department of Pediatrics University of Colorado School of Medicine The Children s Hospital Anschutz Medical Campus
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
School of Public Health University of Sydney Quantifying Life expectancy in people with Type 2 diabetes Alison Hayes School of Public Health University of Sydney The evidence Life expectancy reduced by
Hypoglycemia: A Complication When Targeting Type 2 Diabetes Jeffrey S. Freeman DO FACOI Professor of Internal Medicine Chairman Division of Endocrinology and Metabolism Philadelphia College of Osteopathic
Background: Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope November 19, 2015 The Centers for Disease Control
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 25 September 2008 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE
Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
Primary Prevention of Cardiovascular Disease with a Mediterranean diet Alejandro Vicente Carrillo, Brynja Ingadottir, Anne Fältström, Evelyn Lundin, Micaela Tjäderborn GROUP 2 Background The traditional
European Medicines Agency London, 19 July 2007 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR
Quick reference guide for health professionals Absolute cardiovascular disease risk assessment This quick reference guide is a summary of the key steps involved in assessing absolute cardiovascular risk
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
Component of Statistics Canada Catalogue no. 82-625-X Health Fact Sheets Article Heart health and cholesterol levels of Canadians, 2007 to 2009 March How to obtain more information For information about
Learn and Live SM ACCF/AHA Pocket Guideline Based on the 2010 ACCF/AHA Guideline Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults November 2010 Guideline for Assessment of Cardiovascular
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate
The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery Michael E. Farkouh, MD, MSc Peter Munk Chair in Multinational Clinical Trials Director, Heart and Stroke
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
La salute e medicina di genere la ricerca sul campo focus su diabete e malattie croniche Genere e rischio cardiovascolare nel diabete. Giuseppe Seghieri Pistoia 7 giugno 2016, Ospedale San Jacopo _ Sala
King s Diabetes Research Group Is hypoglycemia an issue in type 2 diabetes? Stephanie A Amiel RD Lawrence Professor of Diabetic Medicine King s College London Conflicts of interest None! (Currently working
STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015 PROJECT TITLE: Analysis of ECG Exercise Stress Testing and Framingham Risk Score in Chest Pain Patients PRIMARY SUPERVISOR NAME: Dr. Edward Tan DEPARTMENT:
ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE I- BACKGROUND: Coronary artery disease and stoke are the major killers in the United States.
Statins: Can there be too much of a good thing? Spoiler alert No Oh Contraire Haaaaiiiiiiile No! Frequently under prescribing statin therapy! Typical Case 68 YO Smoker ACS Multiple prior PCI s Multiple
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
SUPPLEMENTAL MATERIAL Table S1. The logistic regression model used to calculate the propensity score. Table S2. Distribution of propensity score among the treat and control groups of the full and matched
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
The Economic Impact and Cost-Effectiveness of Glucose Monitoring William H. Herman, MD, MPH Stefan S. Fajans/GlaxoSmithKline Professor of Diabetes Professor of Internal Medicine and Epidemiology University
DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study National Diabetes Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What
Site ID: Q1: Global risk assessment using PROCAM, SCORE, FRAMINGHAM or REYLDS ecc is sufficient Q2: The value of an emerging test is best assessed using C - statistics Q3: Atherosclerosis imaging may be
Hull & East Riding Prescribing Committee PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION For guidance on Primary Prevention please see NICE guidance http://www.nice.org.uk/guidance/cg181
Improving drug prescription in elderly diabetic patients FRANCESC FORMIGA Hospital Universitari de Bellvitge High prevalence, but also increases the incidence. The older the patients, the higher the percentages
CARDIAC OUTCOMES AFTER MYOCARDIAL INFARCTION IN ELDERLY PATIENTS WITH DIABETES MELLITUS By Deborah Chyun, RN, PhD, Viola Vaccarino, MD, PhD, Jaime Murillo, MD, Lawrence H. Young, MD, and Harlan M. Krumholz,
How to train the cardiovascular patient? Physical activity in patients with heart disease: how much is good enough? Per Anton Sirnes MD.Phd.FESC Moss, Norway Chair, ESC Council on Cardiology Practice Conflicts
Research Journal of Pharmaceutical, Biological and Chemical Sciences Prevalence of Microalbuminuria in relation to HbA1c among known Type2 Diabetic Patients in Puducherry population Muraliswaran P 1 *,
Diabetes and Heart Disease Diabetes and Heart Disease According to the American Heart Association, diabetes is one of the six major risk factors of cardiovascular disease. Affecting more than 7% of the
Dyslipidemia and type 2 diabetes mellitus History: A 17-year-old Hispanic female patient is seen for a routine clinic follow-up visit. She was diagnosed with type 2 diabetes 6 months ago. Her hemoglobin
NHS Diabetes Prevention Programme (NHS DPP) Non-diabetic hyperglycaemia Produced by: National Cardiovascular Intelligence Network (NCVIN) Date: August 2015 About Public Health England Public Health England
METABOLIC SYNDROME AN INTEGRATIVE APPROACH AN OPPORTUNITY FOR PHARMACISTS TO MAKE A DIFFERENCE Mike Rizo, Pharm D, MBA, ABAAHP THE EVOLUTION OF THE PHARMACIST 1920s 1960s 2000s THE PHARMACIST OF THE FUTURE?
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
REDESIGNING TREATMENT STRATEGIES IN TYPE 2 DIABETES BY TREATMENT INTENSIFICATION AND PATIENT EDUCATION by LAKSHMI SUBRMANYA RAO B Pharmacy, Rajiv Gandhi University of Health Sciences, India 2008 M S in
CLINICAL TRIAL OVERVIEW: ROLE OF CHOLESTEROL-REDUCING AGENTS IN PATIENTS WITH DIABETES * Lawrence A. Leiter, MD, FRCPC, FACP ABSTRACT Approximately 80% of diabetic patients will die of vascular disease,
Type 1 Diabetes W ( Juvenile Diabetes) hat is Type 1 Diabetes? Type 1 diabetes, also known as juvenile-onset diabetes, is one of the three main forms of diabetes affecting millions of people worldwide.
MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY In order to improve the efficiency of PINNACLE Registry data analytics, a missing data analysis has been conducted on PINNACLE Registry data
Expert Commentary A response to the recent JAMA meta analysis on omega 3 supplementation and cardiovascular events Dr. Bruce J. Holub, Ph.D., Professor Emeritus, University of Guelph Expert Commentary:
International Task Force for Prevention Of Coronary Heart Disease Clinical management of risk factors of coronary heart disease and stroke Economic analyses of primary prevention of coronary heart disease
Chapter 7: Strengthen the Role & Impact of Ill Health Prevention Diabetes Lead author: Dr Sapna Chauhan Introduction Diabetes is a major public health issue. There are currently around 3.8 million people
Clinical Practice Guidelines for Diabetes Management Diabetes is a disease in which blood glucose levels are above normal. Over the years, high blood glucose damages nerves and blood vessels, which can
Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die
Atherosclerosis of the aorta Artur Evangelista Atherosclerosis of the aorta Diagnosis Classification Prevalence Risk factors Marker of generalized atherosclerosis Risk of embolism Therapy Diagnosis Atherosclerosis
International Scholarly Research Network ISRN Cardiology Volume 2012, Article ID 874706, 5 pages doi:10.5402/2012/874706 Clinical Study The Sweet Spot: Continued Search for the Glycemic Threshold for Macrovascular
Randomized trials versus observational studies The case of postmenopausal hormone therapy and heart disease Miguel Hernán Harvard School of Public Health www.hsph.harvard.edu/causal Joint work with James
Starting Insulin Sooner Than Later Rotorua GP Insulin Seminar 13 June 2014 Kingsley Nirmalaraj MBBS, FRACP, FACE Consultant Endocrinologist and Physician Tauranga Hospital/ Bay Endocrinology Ltd Declaration
Diabetes, hypertension and a lot more `in the elderly` JORIS SCHAKEL INTERNIST- CLINICAL GERIATRICIAN JGSCHAKEL@SEHOS.CW IT`S HARD TO GIVE GENERAL ADVICE! ``The Elderly`` Heterogeneous group ;widely varying
How can registries contribute to guidelines? Nicolas DANCHIN, HEGP, Paris Pros and cons of registers Prospective randomised trials constitute the cornerstone of "evidence-based" medicine, and they therefore
Acute Coronary Syndrome What Every Healthcare Professional Needs To Know Background of ACS Acute Coronary Syndrome (ACS) is an umbrella term used to cover a spectrum of clinical conditions that are caused
ONLINE SUPPLEMENT Role of elevated heart rate in the development of cardiovascular disease in By Palatini P Department of Clinical and Experimental Medicine University of Padova, Padua, Italy Running title:
Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Jean-Luc MONIN, MD, PhD Henri Mondor University Hospital Créteil, FRANCE Disclosures : None 77-year-old woman, mild dyspnea
Scottish Diabetes Survey 2011 Scottish Diabetes Survey Monitoring Group Foreword The Scottish Diabetes Survey 2011 data reflects many aspects of the quality of diabetes care across the whole of Scotland.
March 3, 2012 BD Response to FDA statement regarding Statins The Food and Drug Administration announced on Tuesday (February 28, 2012) the changes to the safety information on the labels of statins regarding
Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost Naftali Stern Institute of Endocrinology, Metabolism and Hypertension Tel Aviv -Sourasky Medical Center and Sackler
Leicester Nuffield Research Unit Trends in disease and how they will impact on disability in the older population R. Matthews, C. Jagger & MRC CFAS Background Projections of future numbers with disability
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
Coronary Calcium Background Ahtherosclerosis: Maturation of a plaque into symptomatic disease Coronary Artery disease Fatty Streak: Autopsy, seen in autopsy Occurs very early, 0s, late teens Seen almost
Perioperative Cardiac Evaluation Caroline McKillop Advisor: Dr. Tam Psenka 10-3-2007 Importance of Cardiac Guidelines -Used multiple times every day -Patient Safety -Part of Surgical Care Improvement Project
Treatment of Diabetic Patient with Multivessel Coronary Artery Disease: the Surgeon Perspective Fabio B. Jatene Full Professor of Cardiovascular Surgery Heart Institute - HC-FMUSP email@example.com
Cholesterol a biomolecule Bad cholesterol a strange tale Good cholesterol - indeed Thomas B. Kuhn: University of Alaska, Cereon Biotechnology LLC This document is protected by copyright Dr. Thomas B. Kuhn
Using an EMR to Improve Quality of Care in a National Network James M. Gill, MD, MPH Associate Professor of Family Medicine Senior Scientist in Health Policy Jefferson Medical College, Philadelphia, PA
Measure #317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented National Quality Strategy Domain: Community / Population Health 2016 PQRS OPTIONS F INDIVIDUAL MEASURES: